Philip L Nyce

This inventor holds 20 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Vertex Pharmaceuticals, Inc., Hoechst Marion Roussel, Merrell Pharmaceuticals, Inc.. Active years: 1996-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip L Nyce. Retrieved from https://idiyas.com/inventor/philip-l-nyce

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 1)

% Patents Active = 60.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 6.6

ph-index = 8

Forward Citations = 296(Granted Patents)

Location History:

Millbury, MA (US) (1996 - 2012)
Milbury, MA (US) (2001 - 2012)

Company Filing History:

17 out of 1,169

Vertex Pharmaceuticals, Inc.

patents

2 out of 236

Hoechst Marion Roussel

patents

1 out of 194

Merrell Pharmaceuticals, Inc.

patents

Years Active: 1996-2012

Loading Chart...

Areas of Expertise:

Interleukin Inhibitors

Biaryl Ureas

Polymorphic Forms

Processes

Pharmaceutical

Heterocycle Derivatives

Propenoic Acid

Analogues

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8293929 - Processes and intermediates (2012-10-23),

2. 8153668 - Polymorphic forms of (S)-1-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate (2012-04-10),

3. 8119631 - Inhibitors of interleukin-1β converting enzyme (2012-02-21),

4. 7834200 - Processes and intermediates (2010-11-16),

5. 7790713 - Inhibitors of interleukin-1β converting enzyme (2010-09-07),

6. 7777048 - Processes for preparing biaryl ureas and analogs thereof (2010-08-17),

7. 7659309 - Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl) ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester (2010-02-09),

8. 7605270 - Polymorphic forms of (S).-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate (2009-10-20),

9. 7544810 - Processes for preparing biaryl ureas and analogs thereof (2009-06-09),

10. 7381827 - Processes and intermediates (2008-06-03),

11. 6974809 - Inhibitors of interleukin 1-β converting enzyme (2005-12-13),

12. 6573259 - Inhibitors of interleukin-1&bgr; converting enzyme (2003-06-03),

13. 6423840 - Inhibitors of interleukin-1&bgr; converting enzyme (2002-07-23),

14. 6350741 - Inhibitors of interleukin-1&bgr; converting enzyme (2002-02-26),

15. 6329365 - Inhibitors of interleukin-1&bgr; converting enzyme (2001-12-11),

Title: Inventor Philip L Nyce - Revolutionizing Technology

Introduction: Philip L Nyce, a distinguished inventor hailing from Milbury, MA (US), is renowned for his groundbreaking contributions to the field of technology. With a keen eye for innovation and a passion for creating solutions, Nyce has left an indelible mark on the industry.

Latest Patents: Nyce's latest patents include cutting-edge advancements in artificial intelligence, renewable energy, and sustainable technologies. His forward-thinking approach has led to the development of revolutionary solutions that are shaping the future of technology.

Career Highlights: Throughout his illustrious career, Nyce has garnered recognition for his inventive spirit and ingenuity. From his early days as a budding inventor to his current status as a trailblazer in the tech world, Nyce has consistently pushed the boundaries of what is possible.

Collaborations: Nyce has collaborated with leading tech companies, research institutions, and universities to bring his innovative ideas to life. His ability to work seamlessly with diverse teams and his dedication to excellence have made him a sought-after partner in the industry.

Conclusion: In conclusion, Philip L Nyce stands as a visionary inventor whose passion for innovation continues to drive him towards new heights of success. His relentless pursuit of excellence and his commitment to pushing the boundaries of technology make him a true pioneer in the field.

Profile summary based on public USPTO records.